Cat. No.: HY-B0425

Novobiocin

(Synonyms: Albamycin; Cathomycin)

12 Cited Publications

Customer Review

Based on 12 publication(s) in Google Scholar

Novobiocin (Albamycin) is a potent and orally active antibiotic. Novobiocin also is a DNA gyrase inhibitor and a heat shock protein 90 (Hsp90) antagonist. Novobiocin has the potential for the research of highly beta-lactam-resistant pneumococcal infections. Novobiocin shows anti-orthopoxvirus activity.

For research use only. We do not sell to patients.

Purity: 97.88%
CAS No.: 303-81-1
Formula: C₃₁H₃₆N₂O₁₁
Molecular Weight:612.62

Storage:

-20°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Novobiocin Chemical Structure

CAS No.: 303-81-1

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (12)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

β-lactam

HSP90

All Antibiotic Isoforms :

All DNA/RNA Synthesis Isoforms :

All HSP Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
HCC1937	IC₅₀	>80 μM Compound: Novobiocin	Antiproliferative activity against BRCA1-deficient human HCC1937 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay Antiproliferative activity against BRCA1-deficient human HCC1937 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay	[PMID: 38375763]
HCT-116	IC₅₀	>80 μM Compound: Novobiocin	Antiproliferative activity against BRCA2-deficient human HCT-116 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay Antiproliferative activity against BRCA2-deficient human HCT-116 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay	[PMID: 38375763]
HEK-293T	IC₅₀	>100 μM Compound: NB	Cytotoxicity against HEK293T cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against HEK293T cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 38107168]
HepG2	IC₅₀	>32 μg/mL Compound: Novobiocin 1	Cytotoxicity against human HepG2 cells after 24 hrs by CellTiter-Glo assay Cytotoxicity against human HepG2 cells after 24 hrs by CellTiter-Glo assay	[PMID: 30122228]
Huh-7	CC₅₀	1103.18 μg/mL Compound: 33	Cytotoxicity against human HuH7 cells by MTT assay Cytotoxicity against human HuH7 cells by MTT assay	[PMID: 31549836]
LNCaP	IC₅₀	420 μM Compound: NB	Antiproliferative activity against human LNCAP cells Antiproliferative activity against human LNCAP cells	[PMID: 21129982]
MCF-10A	IC₅₀	>80 μM Compound: Novobiocin	Antiproliferative activity against human MCF-10A cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay Antiproliferative activity against human MCF-10A cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay	[PMID: 38375763]
MCF7	GI₅₀	260 μM Compound: NVB	Growth inhibition of ER-positive human MCF7 cells after 72 hrs by MTT assay Growth inhibition of ER-positive human MCF7 cells after 72 hrs by MTT assay	[PMID: 24992077]
MCF7	IC₅₀	256 μM Compound: 31	Antiproliferative activity against human MCF7 cells Antiproliferative activity against human MCF7 cells	[PMID: 31663736]
MCF7	IC₅₀	260 μM Compound: Novobiocin	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth	[PMID: 34952432]
MCF7	IC₅₀	260 μM Compound: NVB	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation	[PMID: 24992077]
MCF7	IC₅₀	260 μM Compound: NVB, novobiocin	Growth inhibition of MCF7 cells after 72 hrs by MTT assay Growth inhibition of MCF7 cells after 72 hrs by MTT assay	[PMID: 17979263]
MCF7	IC₅₀	293.3 μM Compound: Novobiocin	Antiproliferative activity against human MCF7 cells measured after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells measured after 48 hrs by MTT assay	[PMID: 27153346]
MCF7	IC₅₀	357 μM Compound: 1a, NB	Cytotoxicity against ER-positive human MCF7 cells expressing low level of HER2 after 3 days by MTT assay Cytotoxicity against ER-positive human MCF7 cells expressing low level of HER2 after 3 days by MTT assay	[PMID: 23859777]
MCF7	IC₅₀	481.3 μM Compound: novobiocin	Antiproliferative activity against human MCF7 cells expressing ER Antiproliferative activity against human MCF7 cells expressing ER	[PMID: 20570149]
MCF7	IC₅₀	85.1 μM Compound: Novobiocin	Inhibition of BCRP expressed in MCF7 MX cells by Hoechst 33342 staining Inhibition of BCRP expressed in MCF7 MX cells by Hoechst 33342 staining	[PMID: 19932960]
MDA-MB-436	IC₅₀	24.3 μM Compound: Novobiocin	Antiproliferative activity against BRCA1-deficient human MDA-MB-436 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay Antiproliferative activity against BRCA1-deficient human MDA-MB-436 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay	[PMID: 38375763]
MDA-MB-468	IC₅₀	338.4 μM Compound: Novobiocin	Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs by MTT assay	[PMID: 27153346]
MDCK	IC₅₀	104 μM Compound: Novobiocin	Inhibition of BCRP expressed in MDCK cells by pheophorbide A assay Inhibition of BCRP expressed in MDCK cells by pheophorbide A assay	[PMID: 19932960]
Sf9	IC₅₀	210 nM Compound: 1	Inhibition of Escherichia coli His6-tagged ParC/ParE expressed in baculovirus-infected Sf9 cells by gel electrophoresis Inhibition of Escherichia coli His6-tagged ParC/ParE expressed in baculovirus-infected Sf9 cells by gel electrophoresis	[PMID: 21235241]
SH-SY5Y	EC₅₀	48.39 nM Compound: novobiocin	Neuroprotection against beta-amyloid peptide 1-42-induced toxicity in human SH-SY5Y cells assessed as lactate dehydrogenase release Neuroprotection against beta-amyloid peptide 1-42-induced toxicity in human SH-SY5Y cells assessed as lactate dehydrogenase release	[PMID: 19138859]
SK-BR-3	EC₅₀	700 μM Compound: 1	Antiproliferative activity against human SKBR3 cells Antiproliferative activity against human SKBR3 cells	[PMID: 29720349]
SK-BR-3	IC₅₀	~ 700 μM Compound: 1	Antiproliferative activity against human SK-BR-3 cells Antiproliferative activity against human SK-BR-3 cells	[PMID: 38516588]
SK-BR-3	IC₅₀	350 μM Compound: 1a, NB	Cytotoxicity against ER-negative human SKBR3 cells expressing high level of HER2 after 3 days by MTT assay Cytotoxicity against ER-negative human SKBR3 cells expressing high level of HER2 after 3 days by MTT assay	[PMID: 23859777]
SK-BR-3	IC₅₀	474.7 μM Compound: novobiocin	Antiproliferative activity against human ER deficient SKBR3 cells over expressing HER2 Antiproliferative activity against human ER deficient SKBR3 cells over expressing HER2	[PMID: 20570149]
SK-BR-3	IC₅₀	700 mM Compound: 1	Antiproliferative activity against human SKBR3 cells Antiproliferative activity against human SKBR3 cells	[PMID: 24953820]
SK-BR-3	IC₅₀	700 μM Compound: 1	Antiproliferative activity against human SKBR3 cells after 72 hrs by MTS/PMS assay Antiproliferative activity against human SKBR3 cells after 72 hrs by MTS/PMS assay	[PMID: 19932969]
SK-BR-3	IC₅₀	700 μM Compound: 1	Antiproliferative activity against human SKBR3 cells after 72 hrs by MTS assay Antiproliferative activity against human SKBR3 cells after 72 hrs by MTS assay	[PMID: 24900777]
SK-BR-3	IC₅₀	700 μM Compound: 1	Antiproliferative activity against human SKBR3 cells Antiproliferative activity against human SKBR3 cells	[PMID: 25699150]
SK-BR-3	IC₅₀	700 μM Compound: 5	Antiproliferative activity against human SKBR3 cells after 72 hrs by MTS/PMS assay Antiproliferative activity against human SKBR3 cells after 72 hrs by MTS/PMS assay	[PMID: 25462258]
SK-BR-3	IC₅₀	700 μM Compound: Novobiocin	Antiproliferative activity against human SKBR3 cells expressing HER2 after 72 hrs by MTS/PMS assay Antiproliferative activity against human SKBR3 cells expressing HER2 after 72 hrs by MTS/PMS assay	[PMID: 21553822]
SK-BR-3	IC₅₀	700 μM Compound: Novobiocin	Antiproliferative activity against human SKBR3 cells Antiproliferative activity against human SKBR3 cells	[PMID: 23234644]
SK-BR-3	IC₅₀	700 μM Compound: Novobiocin	Antiproliferative activity against human SKBR3 cells Antiproliferative activity against human SKBR3 cells	[PMID: 23606927]
SK-BR-3	IC₅₀	700 μM Compound: Novobiocin	Cytotoxicity against human SKBR3 cells by MTS assay Cytotoxicity against human SKBR3 cells by MTS assay	[PMID: 26745854]
SK-BR-3	IC₅₀	700 μM Compound: Novobiocin	Antiproliferative activity against human SKBR3 cells after 72 hrs by MTS assay Antiproliferative activity against human SKBR3 cells after 72 hrs by MTS assay	[PMID: 30048133]
SK-BR-3	IC₅₀	700 μM Compound: Novobiocin	Inhibition of human SKBR3 cell proliferation Inhibition of human SKBR3 cell proliferation	10.1039/C0MD00063A
SK-OV-3	IC₅₀	>80 μM Compound: Novobiocin	Antiproliferative activity against BRCA-proficient human SK-OV-3 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay Antiproliferative activity against BRCA-proficient human SK-OV-3 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay	[PMID: 38375763]
SW48	IC₅₀	>80 μM Compound: Novobiocin	Antiproliferative activity against BRCA2-deficient human SW48 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay Antiproliferative activity against BRCA2-deficient human SW48 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay	[PMID: 38375763]
TERT-RPE1	IC₅₀	358.4 μM Compound: 24; NVB	Antiproliferative activity against P53 knockout human RPE-1 cells assessed as inhibition of cell growth by CellTiter-Glo assay Antiproliferative activity against P53 knockout human RPE-1 cells assessed as inhibition of cell growth by CellTiter-Glo assay	[PMID: 37134182]
TERT-RPE1	IC₅₀	86 μM Compound: 24; NVB	Antiproliferative activity against BRCA1 knockout human RPE-1 cells assessed as inhibition of cell growth by CellTiter-Glo assay Antiproliferative activity against BRCA1 knockout human RPE-1 cells assessed as inhibition of cell growth by CellTiter-Glo assay	[PMID: 37134182]
TERT-RPE1	IC₅₀	97.24 μM Compound: 24; NVB	Antiproliferative activity against P53 and BRCA1 knockout human RPE-1 cells assessed as inhibition of cell growth by CellTiter-Glo assay Antiproliferative activity against P53 and BRCA1 knockout human RPE-1 cells assessed as inhibition of cell growth by CellTiter-Glo assay	[PMID: 37134182]
Vero	CC₅₀	850.5 μg/mL Compound: 33	Cytotoxicity against African green monkey Vero cells by MTT assay Cytotoxicity against African green monkey Vero cells by MTT assay	[PMID: 31549836]
Vero	EC₅₀	15.21 μg/mL Compound: 33	Inhibition of NS2B-NS3 protease in Zika virus Puerto Rico/PRVABC5 infected in African green monkey Vero cells assessed as antiviral activity measured 48 hrs post infection by RT-PCR method Inhibition of NS2B-NS3 protease in Zika virus Puerto Rico/PRVABC5 infected in African green monkey Vero cells assessed as antiviral activity measured 48 hrs post infection by RT-PCR method	[PMID: 31549836]

In Vitro

Novobiocin (1 mM) competitively inhibits ATP binding to gyrase B to interfere with nucleotide binding and interferes with the association of the co-chaperones Hsc70 and p23 with Hsp90^[1].
Novobiocin (200 µM; 24 h) inhibits the rate of repair of both cis-DDP and BCNU induced DNA interstrand cross-links and with a corresponding decrease in the clonogenic survival of the human glioblastoma multiforme cells^[2].
Novobiocin (0.3 mM; 48 hours) induces a caspase-3/7 enzyme–dependent apoptosis assays with an induction of approximately three- to fivefold of apoptotic cells in K562, HL60, Mutz-2^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Novobiocin (25, 50, 100, 200 mg/kg; s.c.; 4 times at 1, 5, 24 and 48 h after infection) shows anti-infection activity in mice infected with amoxicillin-resistant Streptococcus pneumoniae^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

30 g adult female Swiss mice (sepsis induced by the penicillin-susceptible strain (AR33118))^[3]
Dosage:

25, 50, 100, 200 mg/kg
Administration:

S.c.; given at 1, 5, 24 and 48 h after infection
Result:

Showed anti-infection activity in mice infected with amoxicillin-resistant S. pneumoniae.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 303-81-1
Appearance Solid
Molecular Weight 612.62
Formula C₃₁H₃₆N₂O₁₁
Color White to off-white
SMILES

CC1=C(O2)C(C(O)=C(NC(C3=CC(C/C=C(C)/C)=C(O)C=C3)=O)C2=O)=CC=C1O[C@H]4[C@@H]([C@@H]([C@@H](OC)C(C)(C)O4)OC(N)=O)O
Synonyms

Albamycin; Cathomycin
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

-20°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (12)

All Bio/Physico-chemical AssayCell Imaging/StainingCell Proliferation/Viability AssayWB

Sort by:

Journal Impact Factor

Nat Methods

Efficient high-precision homology-directed repair-dependent genome editing by HDRobust. [Abstract]

2023 Sep;20(9):1388-1399. PMID: 37474806

Novobiocin purchased from MedChemExpress. Usage Cited in: Nat Methods. 2023 Sep;20(9):1388-1399. [Abstract]

Editing efficiencies of the VCAN target using Cas9D10A double nicking in H9 hESCs carrying the K3753R mutation and additional small molecules to inhibit the MMEJ repair proteins Polϴ, PARP or Ligase I/III: Novobiocin.
Blood

Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response. [Abstract]

2018 Jul 19;132(3):307-320. PMID: 29724897

Novobiocin purchased from MedChemExpress. Usage Cited in: Blood. 2018 Jul 19;132(3):307-320. [Abstract]

K562, KCL22 and HL60 are treated with the indicated (cytotoxic) concentration of Amidopyrine (AX), Novobiocin (NB) and AUY922 for 48h and later protein lysates are subjected to immunoblot analysis.
Adv Sci (Weinh)

SRSF5-Mediated Alternative Splicing of M Gene is Essential for Influenza A Virus Replication: A Host-Directed Target Against Influenza Virus. [Abstract]

2022 Dec;9(34):e2203088. PMID: 36257906
Cell Rep Med

A CD36-dependent non-canonical lipid metabolism program promotes immune escape and resistance to hypomethylating agent therapy in AML. [Abstract]

2024 May 29:101592. PMID: 38843841
PLoS Pathog

Anti-orthopoxvirus drugs inhibit lumpy skin disease virus replication by targeting viral DNA polymerase. [Abstract]

2026 Jan 26;22(1):e1013903. PMID: 41587213
Int J Mol Sci

Cisplatin Synergistically Enhances Antitumor Potency of Conditionally Replicating Adenovirus via p53 Dependent or Independent Pathways in Human Lung Carcinoma. [Abstract]

2019 Mar 5;20(5). pii: E1125. PMID: 30841620

Novobiocin purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2019 Mar 5;20(5). pii: E1125. [Abstract]

Cell viability assay to analyze the impact of Probenecid and Novobiocin treatments on resistance.
J Med Virol

Drug Repurposing: In Vitro Evaluation of Simeprevir as a Novel Antiviral Drug Against Severe Fever With Thrombocytopenia Syndrome Virus. [Abstract]

2025 Oct;97(10):e70655. PMID: 41117261

Novobiocin purchased from MedChemExpress. Usage Cited in: J Med Virol. 2025 Oct;97(10):e70655. [Abstract]

Novobiocin also reduced NP expression at 25 μM, with mean fluorescence intensities significantly lower than those of the untreated control.

Novobiocin purchased from MedChemExpress. Usage Cited in: J Med Virol. 2025 Oct;97(10):e70655. [Abstract]

Cytoxicity and inhibition of Novobiocin, EC50 = 25.12 μM.
Mol Pharm

Machine Learning Models Identify New Inhibitors for Human OATP1B1. [Abstract]

2022 Nov 7;19(11):4320-4332. PMID: 36269563
Cancer Res Commun

Inhibition of NEK2 Promotes Chemosensitivity and Reduces KSHV-positive Primary Effusion Lymphoma Burden. [Abstract]

2024 Apr 9;4(4):1024-1040. PMID: 38592451
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
Surgery

Overexpression of human DNA polymerase theta is a biomarker of aggressive and DNA repair-deficient papillary thyroid cancers. [Abstract]

2024 Jun 18:S0039-6060(24)00303-9. PMID: 38897886
bioRxiv

2025 Sep 15.

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (163.23 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.6323 mL

8.1617 mL

16.3233 mL

5 mM

0.3265 mL

1.6323 mL

3.2647 mL

10 mM

0.1632 mL

0.8162 mL

1.6323 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 5 mg/mL (8.16 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 5 mg/mL (8.16 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Marcu MG, et al. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J Biol Chem. 2000 Nov 24;275(47):37181-6. [Content Brief]

[2]. Ali-Osman F, et al. Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells. Cancer Res. 1993 Dec 1;53(23):5663-8. [Content Brief]

[3]. Rodríguez-Cerrato V, et al. Comparative efficacy of novobiocin and amoxicillin in experimental sepsis caused by beta-lactam-susceptible and highly resistant pneumococci. Int J Antimicrob Agents. 2010 Jun;35(6):544-9. [Content Brief]

[4]. Eder JP, et al. A phase I clinical trial of novobiocin, a modulator of alkylating agent cytotoxicity. Cancer Res. 1991 Jan 15;51(2):510-3. [Content Brief]

[5]. Bhatia S, et al. Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response.Blood. 2018 Jul 19;132(3):307-320. [Content Brief]

[6]. Smee DF. Progress in the discovery of compounds inhibiting orthopoxviruses in animal models. Antivir Chem Chemother. 2008;19(3):115-24. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.6323 mL	8.1617 mL	16.3233 mL	40.8083 mL
	5 mM	0.3265 mL	1.6323 mL	3.2647 mL	8.1617 mL
	10 mM	0.1632 mL	0.8162 mL	1.6323 mL	4.0808 mL
	15 mM	0.1088 mL	0.5441 mL	1.0882 mL	2.7206 mL
	20 mM	0.0816 mL	0.4081 mL	0.8162 mL	2.0404 mL
	25 mM	0.0653 mL	0.3265 mL	0.6529 mL	1.6323 mL
	30 mM	0.0544 mL	0.2721 mL	0.5441 mL	1.3603 mL
	40 mM	0.0408 mL	0.2040 mL	0.4081 mL	1.0202 mL
	50 mM	0.0326 mL	0.1632 mL	0.3265 mL	0.8162 mL
	60 mM	0.0272 mL	0.1360 mL	0.2721 mL	0.6801 mL
	80 mM	0.0204 mL	0.1020 mL	0.2040 mL	0.5101 mL
	100 mM	0.0163 mL	0.0816 mL	0.1632 mL	0.4081 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Novobiocin

Anti-Infection Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Metabolism/Protease Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antibacterial Compound Library

Endoplasmic Reticulum Stress Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Antiviral Traditional Chinese Medicine Active Compound Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Orthopoxvirus Compound Library

Heterocyclic Compound Library

Withdrawn Drug Compound Library

Off-patent Drug Library

Metabolic Enzyme Compound Library

Cell Death Library

FDA-Approved Traditional Chinese Medicine Active Compound Library

Extracellular Vesicles (EVs) Compound Library

Anti-Drug-Resistant Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Mongolian Medicine Compound Library

Publications Citing Use of MedChemExpress (MCE) Novobiocin

All Antibiotic Isoforms

All DNA/RNA Synthesis Isoforms

All HSP Isoforms

Biological Activity

Chemical Information

Publications (12)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Novobiocin Related Classifications

Cat. No.: HY-B0425